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ABSTRACT
Background: Testosterone has been associated with cardiovascular (CV) health in men and women 
with or without diabetes. There are however conflicting results which warrant further investigations 
to understand if testosterone is important for prognosis, in particular in relation to diabetes and 
cardiovascular disease (CVD). To gain further insight, several aspects such as when and which 
testosterone fraction to assess as well as genetic variations in the androgen receptor are of interest to 
study.
Aims: To study the role of testosterone in men and women with different levels of dysglycemia and 
CVD by investigating:
1. the dynamics of testosterone levels up to a year following an acute myocardial infarction 
(AMI) in men with and without dysglycemia
2. the relation between the androgen receptor gene CAG repeat length, testosterone levels and 
prognosis
3. the prognostic implications of total testosterone, free testosterone and the binding protein sex 
hormone-binding globulin (SHBG) in patients with AMI compared to healthy controls as 
well as in men and women with dysglycemia and high CV risk
Methods: Studies I and II were based on data from the GAMI study, a prospective cohort study 
of patients with AMI providing blood samples at four time points up to a year post-infarction, 
and healthy, age-matched controls. Study participants were classified as having normal (NGT) or 
abnormal glucose tolerance (AGT) based on oral glucose tolerance tests and followed for about 
11 years for CV events, and CV and all-cause mortality; Study I comprised male patients (n=123) 
and controls (n=124), Study II comprised male patients (n=121) with blood samples available for 
DNA analyses. Studies III and IV were based on a biomarker substudy of ORIGIN which was 
a large, multicenter randomized controlled trial following patients with dysglycemia and high CV 
risk for about six years for CV events and all-cause mortality. Study III comprised all male patients 
(n=5 553) and Study IV all female patients (n=2 848) in the biomarker substudy. 
Results: In Study I, median testosterone levels were lower immediately after an AMI compared to 
controls at baseline (243 ng/dl vs. 380 ng/dl; p<0.01) but increased at discharge, three months and 12 
months to 311, 345 and 357 ng/dl respectively. Patients with AGT had the lowest levels at the first 
timepoint (230 ng/dl). Total and free testosterone did not predict CV events or all-cause mortality in 
men with AMI but CV and all-cause mortality in controls.
In Study II, contrary to the hypothesis, there was no correlation between CAG repeat length and 
testosterone and moreover CAG repeat length did not predict CV events or all-cause mortality. 
In Study III, total and free testosterone did not predict prognosis in Cox regression analyses by one 
standard deviation increment but low free testosterone (≤7 ng/dl) was associated with increased all-
cause mortality. Additionally, increasing SHBG was related to a higher risk of CV events (HR 1.07; 
95% CI 1.00–1.14; p<0.03) and all-cause mortality (HR 1.13; 95% CI 1.06–1.21; p<0.01).
Finally, in Study IV, total and free testosterone did not predict any outcomes in women but SHBG 
was related to increased all-cause mortality (HR 1.14; 95% CI 1.05-1.24; p<0.01). 
Conclusions: Low testosterone was common in patients hospitalized with AMI, in particular in those 
with AGT, but increased over time indicating that samples taken in close proximity to AMI should 
be interpreted with caution. In contrast to healthy controls where low total and free testosterone 
was predictive of prognosis, only free testosterone ≤7 ng/dl was associated with all-cause mortality 
in patients. This suggests that testosterone may be a mediator in CVD and prognosis rather than 
a traditional risk factor. The potential importance of CAG repeat length in this context was not 
confirmed. Interestingly, SHBG was an independent predictor for CV events and all-cause mortality 
in men and for all-cause mortality in women with dysglycemia. This warrants further study to clarify 
whether the actions of SHBG are mediated through an impact on the distribution of testosterone or if 
SHBG is a direct prognostic marker.
          Testosterone, cardiovascular disease and dysglycemia
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SAMMANFATTNING
Bakgrund: Testosteron tycks vara kopplat till kardiovaskulär sjukdom hos män och kvinnor med 
eller utan diabetes. Tillgängliga data är dock bristfälliga med många kunskapsluckor och ytterligare 
studier behövs för att förstå om testosteron är viktigt ur en prognostisk synvinkel, särskilt i relation till 
kardiovaskulär sjukdom och diabetes. Flera aspekter såsom när och vilken fraktion av testosteron som 
ska mätas samt genetiska variationer i androgenreceptorn är av intresse att studera.
Mål: Att studera testosteronets roll hos män och kvinnor med olika nivåer av dygslykemi och 
kardiovaskulär sjukdom genom att undersöka:
1. dynamiken av testosteronnivåer upp till ett år efter en hjärtinfarkt hos män med eller utan 
dysglykemi
2. kopplingen mellan antal CAG repetitioner i androgenreceptorgenen och testosteronnivåer samt 
prognos.
3. totalt och fritt testosteron samt SHBGs prognostiska betydelse hos patienter med hjärtinfarkt 
jämfört med hos friska kontroller och hos män och kvinnor med dysglykemi och hög 
kardiovaskulär risk. 
Metoder: Studie I och II baserades på GAMI-studien, en prospektiv kohortstudie av hjärtinfarktspatienter 
som lämnade blodprover vid fyra tillfällen upp till ett år efter infarkten samt friska, åldersmatchade 
kontroller. Deltagarna klassificerades med hjälp av ett glukosbelastningstest som att ha normal (NGT) 
eller abnormal glukostolerans (AGT) och följdes i ca 11 år vad avser kardiovaskulära händelser och 
kardiovaskulär och total dödlighet. Studie I inkluderade manliga patienter (n=123) och kontroller (n=124), 
Studie II inkluderade manliga patienter (n=121) med prover tillgängliga för DNA analys. Studie III 
och IV baserades på den biokemiska substudien av ORIGIN som var en stor, multicenter, randomiserad 
kontrollerad studie som följde patienter med dysglykemi och hög risk för kardiovaskulär sjukdom i sex 
år med avseende på kardiovaskulära händelser och total dödlighet. Studie III inkluderade alla manliga 
patienter (n=5 553) och Studie IV alla kvinnliga patienter (n=2 848) i substudien. 
Resultat: I Studie I var medianvärdet av testosteron lägre omedelbart efter en hjärtinfarkt jämfört med 
det hos kontroller (243 ng/dl jfrt. med 380 ng/dl; p<0.01) men steg vid utskrivning, tre månader och 
12 månader till 311, 345 och 357 ng/dl. Patienter med AGT hade lägst nivåer vid den första tidpunkten 
(230 ng/dl). Totalt och fritt testosteron predikterade inte kardiovaskulära händelser eller dödlighet hos 
patienterna med hjärtinfarkt men kardiovaskulär och total dödlighet hos kontrollerna. 
I Studie II förelåg ingen korrelation mellan antal CAG repetitioner och testosteron. Antalet CAG 
repetitioner var ej kopplat till vare sig kardiovaskulära händelser eller total dödlighet. 
I Studie III predikterade varken en standarddeviations ökning av totalt eller fritt testosteron prognos 
i Cox regressionsanalyser, men lågt fritt testosteron (≤7 ng/dl) var kopplat till högre risk för total 
dödlighet. Dessutom var stigande SHBG kopplat till ökad risk för kardiovaskulära händelser (HR 1.07; 
95% CI 1.00–1.14; p<0.03) och total dödlighet. (HR 1.13; 95% CI 1.06–1.21; p<0.01). 
I Studie IV predikterade varken totalt eller fritt testosteron kardiovaskulära händelser eller total 
dödlighet hos kvinnor men högre SHBG var kopplat till ökad dödlighet (HR 1.14; 95% CI 1.05-1.24; 
p<0.01). 
Slutsatser: Lågt testosteron var vanligt hos patienter med akut hjärtinfarkt, särskilt hos de med AGT, 
men steg över tid. Prover tagna i nära anslutning till en hjärtinfarkt bör därför bedömas med försiktighet. 
I motsats till kontrollerna där både lågt totalt och fritt testosteron predikterade prognos var endast fritt 
testosteron ≤7 ng/dl kopplat till ökad mortalitet hos patienter. Detta talar för att testosteron kan vara 
en mediator för kardiovaskulär sjukdom och prognos snarare än en riskfaktor. En faktor av potentiellt 
intresse i detta sammanhang, CAG repetitioner, verkade ej vara viktig hos män med hjärtinfarkt. Å 
andra sidan var SHBG en oberoende prediktor för kardiovaskulära händelser och total dödlighet hos 
män och för dödlighet hos kvinnor med dysglykemi. Huruvida SHBGs effekter förmedlas via dess 
koppling till testosteron eller om SHBG är en direkt prognostisk markör är oklart varför fler studier 
behövs för ökad förståelse kring bakomliggande mekanismer.
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INTRODUCTION
Testosterone
History
In the archeological Roemer-Pelizaeus Museum in Hildesheim, Germany, the statue of 
Hemiuni, the closest advisor to pharaoh Kheops and the architect of the pyramid of Giza 
(fl. 2570 BC) is exhibited (Figure 1). Contrary to the more idealized presentations of males 
from the time period of Ancient Egypt as well-built, athletic men, Hemiunu is portrayed as 
an obese man with no beard and bilateral gynecomastia. The plaque on Hemiunu’s statue 
outlines his professional achievements, but it does not mention family as was customary at 
the time, suggesting he could have been infertile. The statue of Hemiunu is believed to be one 
of the first images of a hypogonadal patient, mirroring testosterone deficiency (1). 
Over time, the basic elements of the testes were 
discovered and described in terms of sperm and 
fertilization, but how endocrine function from 
the testes could present itself in physiological 
appearances was unknown. In the middle of the 
19th century, Arnold Adolph Berthold (1803–1861) 
discovered that following the castration of four 
cockerels, there was a loss of interest in hens (2). 
This was reversed in the two cockerels receiving 
an ectopic testicular transplantation. Berthold 
concluded that “the testes act upon the blood, and 
the blood acts upon the organism as a whole”. These 
findings were confirmed in other animals studies 
in the early 20th century, initiating a search for the 
testicular substance acting in the blood (2).
Simultaneous to the animal experiments, studies 
in the field of steroid hormone biochemistry was 
emerging following the discovery of the steroid 
ring structure. In the 1930s, the German biochemist 
Adolf Butenandt (1903–1995) isolated the 
androgenic steroid androsterone from 15 000 liters 
of urine provided by young policemen and published the chemical synthesis of testosterone 
(3). Butenandt was awarded the Nobel prize in Chemistry in 1939 “for his work on sex 
hormones” together with Leopold Ruzicka (1887-1976) who was awarded the prize “for his 
work on polymethylenes and higher terpenes” that served as a basis for his discoveries on 
testosterone synthesis. Not long thereafter, different forms of testosterone became clinically 
available as injections for the treatment of hypogonadism and trials using testosterone 
therapy were initiated (4). In studies of castrate and eunuchoid patients, testosterone therapy 
was shown to have beneficial effects on peripheral vascular disease (5). Furthermore, case 
reports and a small clinical study (n=46) showed promising results of testosterone therapy 
in patients with angina pectoris (6). This was followed by a somewhat larger study in the 
1940s in which 100 consecutive patients with angina pectoris were prescribed testosterone 
and followed for months to years with regards to their chest discomfort (7). In total, 91 of the 
Figure 1. The statue of Hemiunu. 
Hemiunu was the closest advisor to the 
pharaoh and the architect of the pyramid 
of Giza (fl. 2570 BC). 
https://commons.wikimedia.org/wiki/File:Statue-of-
Hemiun.jpg. Reproduced under the Creative Commons 
Attribution-Share Alike 3.0 Unported license
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100 patients reported moderate to marked improvement. It was concluded that “Testosterone 
propionate, properly used, not only reduces the frequency of attacks of angina pectoris, but 
decreases their severity when they do occur. Further time will be required for the evaluation 
of results before it can be determined definitely whether or not this treatment will prolong 
the life of the patient.”
The role of endogenous and exogenous testosterone in the cardiovascular (CV) system and the 
impact on CV risk factors such as dysglycemia has been studied since with inconsistent results.
 
Regulation and transport of testosterone
Testosterone is a steroid hormone which plays an essential role in sexual and cognitive 
function as well as body development in men (8). The synthesis and release of testosterone 
into the blood from the Leydig cells in the testes is regulated by the hypothalamic-pituitary-
testicular (HPT)-axis and secretion of luteinizing hormone (LH) (Figure 2) (9). Apart from 
that LH regulates the Leydig cell function and testosterone levels, several other endocrine 
pathways such as the insulin-like growth factor 1, thyroid hormones and glucocorticoids are 
believed to affect the regulation of testosterone (10, 11). Moreover, the HPT-axis is sensitive 
to stress and acute illness is associated with a decrease in testosterone levels (12).  
Figure 2. Hypothalamic-pituitary-testicular (HPT) axis. Reproduced with permission from Elsevier 
(26). When the levels of plasma testosterone are low, the HPT axis responds by increasing the 
release of gonadotropin releasing hormone (GnRH) from the hypothalamus and luteinizing hormone 
(LH) from the pituitary gland which stimulates the testes to produce and release more testosterone 
(9). When levels are restored or elevated above normal levels, the HPT axis responds instead by 
decreasing stimulating hormones which result in lower plasma testosterone levels, thereby 
completing a negative feedback loop. LH stimulates Leydig cells to synthesize testosterone and 
follicle stimulating hormone (FSH) stimulates Sertoli Cells to increase spermatogenesis.
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Testosterone is also an important hormone in women, exerting reproductive and non-
reproductive effects as well as acting as a precursor for estradiol synthesis. Levels vary 
during the menstrual cycle with a peak mid-cycle and remain high during the latter phase 
of the cycle (13). Testosterone is in part produced by the ovaries and in part produced by 
peripheral conversion of pre-androsterone from the ovaries and the adrenal gland (1). The 
regulation of testosterone in women is not well-known, but androgen production from the 
ovaries is possibly regulated by the LH levels. 
Testosterone is transported mainly in three fractions in blood in men as well as in women: 
one part bound to sex hormone binding globulin (SHBG) with high affinity, one part bound 
to albumin with low affinity and one small part as unbound free testosterone (Figure 3) 
(14). The proportion transported by the different binding proteins varies slightly between 
men and women with a higher proportion SHBG-bound testosterone in women (14, 15). 
Free testosterone is the fraction that diffuses into target cells and exerts androgenic effects 
(9, 16). The albumin-bound fraction together with free testosterone is called bioavailable 
testosterone. 
Figure 3. Different fractions of testosterone and mechanisms of action. Testosterone circulates 
in blood bound to SHBG, albumin and as an unbound, free fraction. The free fraction can enter 
the cell by different mechanisms, the “free hormone hypothesis” outlined in the figure (16, 19). 
Free testosterone diffuses across the cell membrane and binds to the androgen receptor. After 
binding, the androgen receptor induces dimerization which facilitates the binding to a specific 
sequence of DNA, known as the hormone response element. It regulates transcription of specific 
androgen-responsive genes which in turn promotes synthesis of proteins. Free testosterone can also 
be converted to dihydrotestosterone or estradiol by conversion of enzymes, which are located in 
various parts of the body.
          Testosterone, cardiovascular disease and dysglycemia
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SHBG is a homodimeric glycoprotein, composed of two identical subunits of polypeptide 
chains to which androgens can bind (1, 16, 17). It is produced in the liver and the production is 
inhibited by inflammatory factors such as hepatic lipids, tumor necrosis factor-α, interleukin 
1 and also by high insulin levels. On the other hand, thyroid hormones may e.g. stimulate 
SHBG production. Several conditions such as diabetes, obesity, hypo- and hyperthyroidism, 
kidney disease, liver disease, use of glucocorticoids and androgenic steroids are associated 
with altered SHBG levels (16, 18). SHBG binds testosterone with high affinity, determining 
the bound and free fractions of circulating testosterone and it has been hypothesized that 
SHBG possibly regulates the bioavailability of testosterone.
Studies investigating the molecular interactions between testosterone and SHBG suggest that 
testosterone binds to the two binding sites of SHBG in an equivalent, non-allosteric way, 
and this has served as a basis for formulas used to calculate free testosterone such as the 
Södergård formula and the more commonly used Vermeulen formula (20, 21). However, 
Zakharov et al. recently suggested another mechanism in which a multistep, dynamic process 
of testosterone binding to the SHBG molecule takes place. The binding of testosterone to 
one site of the SHBG dimer leads to an allosteric interaction between the two binding sites, 
resulting in testosterone binding into the second site with a different affinity (22). Calculation 
of free testosterone by means of Zakharov’s model is considered to provide more accurate 
results than previous models (22, 23). 
Mechanisms of testosterone actions
Testosterone exerts effects (Table 1) primarily by binding to the intracellular androgen 
receptor. Different mechanisms by which testosterone enters the cell have been suggested 
whereof the free hormone hypothesis has been depicted in Figure 3. Androgen receptors 
are found in many tissues, including typical androgen-dependent organs such as prostate, 
epididymis, testes and muscles but also the kidneys, spleen and heart (24, 25). Testosterone 
is also converted to other metabolites such as estradiol through activation by aromatase and 
dihydrotestosterone (DHT) through activation by 5α-reductase (Figure 3). 
Table 1. Androgen effects in men (26).
Target organ  Effects
Bone Maintain bone density, bone growth, bone marrow production 
of red blood cells
Brain Cognitive function, memory, libido, emotions
Kidneys Stimulates erytropoetin responsible for red blood cell production
Muscle Increase muscle mass and strength
Skin Hair growth 
Reproductive organs Sperm production, growth of reproductive organs, erectile 
function
Glucose metabolism (27, 28) Insulin sensitivity
Cardiovascular system* (29) Vasodilatation, decrease in atherosclerotic plaque volume, 
shorter QTc interval, protection from ischemic injury
*Associations determined in experimental animal models.
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The androgen receptor gene, located on chromosome X, has different functional domains 
comprising a transactivating, a DNA-binding and a hormone-binding domain respectively. 
The transactivating domain contains a variable number of cytosine-adenosine-guanine 
(CAG) repeat which encodes a polyglutamine stretch of variable length in the receptor 
protein (19, 30). In a European population, the mean length of the CAG repeat in men is 
21-22 (31-33). The peripheral effects of testosterone are dependent on a functional androgen 
receptor and it has been suggested that the number of CAG repeat is inversely correlated to 
the transcriptional activity of the androgen receptor and thereby the androgen effects in target 
tissues (30). Most androgenic effects work through activation of DNA transcription after 
binding to the androgen receptor, but there are also non-genomic effects by interaction with 
cellular membrane receptors although this area is not as well-studied (34). 
In women, testosterone exerts effects either by binding to the androgen receptor or by non-
genomic effects as described for men. It also exerts effects by conversion to estradiol and 
binding to estrogen receptors (13). Testosterone affects bone metabolism, cognitive health, 
gynecological health and sexual function in women. Recently it was also suggested that 
testosterone, as in men, may have effects on the CV and metabolic systems (35). 
Low testosterone levels in men
Hypogonadism is defined as low levels of total testosterone accompanied by related 
symptoms as listed in Table 2 (18). The threshold for low total testosterone varies 
considerably between laboratories and assays but is usually defined as <300 ng/dl or <8-12 
nmol/l (18, 23). There is an even higher variability in the threshold for low free testosterone 
and laboratories are recommended to establish their own lower limit based on equilibrium 
dialysis and/or calculations. The lower limit usually ranges between 5-9 ng/dl or 0.2-0.3 
nmol/L. Measurement or calculation of free testosterone is recommended in conditions 
affecting SHBG as already outlined. Current guidelines discourage testing for testosterone 
deficiency in men recovering from acute illness since testosterone levels are known to be 
affected by stress. Still, it is not clearly described when it is appropriate to assess testosterone 
levels following an acute illness (23).
Table 2. Symptoms and signs typical for testosterone deficiency in men according to the Endocrine 
Society Clinical Practice Guidelines (18, 23).
Symptoms and signs
More specific Less specific
Incomplete or delayed sexual development Decreased energy, self-confidence
Diminished libido Depressed mood
Erectile dysfunction Poor concentration and memory
Hot flushes Trouble with sleep, increased fatigue
Gynecomastia Reduced muscle strength 
Small (<6 ml) or shrinking testes Increased body fat, body mass index
Loss of body hair
Height loss, low bone mineral density
Inability to father children, low/zero sperm 
count
Mild anemia
          Testosterone, cardiovascular disease and dysglycemia
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The HPT-axis serves as a basis for hypogonadism classification (8).  Primary hypogonadism 
is caused by testicular failure while secondary hypogonadism is caused by hypothalamic 
or pituitary failure. Testosterone replacement therapy initiated when the criteria for 
hypogonadism are fulfilled aims at normalizing the testosterone levels, ameliorate symptoms 
and increase the feeling of well-being (18, 23). There are different ways to administer 
testosterone including intramuscular injections at different intervals, transdermal patches, 
topical gels and oral drugs (36). 
The prevalence of low testosterone levels/androgen deficiency varies in different populations 
and seems to increase with age. Androgen deficiency, defined as low total or free testosterone 
in combination with symptoms, was studied in males in the longitudinal Massachusetts Male 
Aging Study and reported as 6% at baseline and 12% after a follow-up of nine years (37). 
In the Baltimore Longitudinal Study of Aging, low testosterone levels (≤325 ng/dl) were 
prevalent in 20% of men between 60-69 years and 30% of those between 70-79 (38). In 
another study of male American veterans (mean age=70 years) a larger proportion (34%) had 
testosterone levels below 300 ng/dl (39). Even if the difference in prevalence may at least 
partly be explained by use of different thresholds, the divergent data underlines the need for 
further studies. 
Low testosterone levels in women 
Testosterone levels are lower in women than in men even if described reference ranges 
varies between different study populations (around 0.3-3.2 nmol/L or 9-92 ng/dl) (1, 
40). Circulating levels of testosterone decline with age but they do not fall specifically at 
menopause (41). Other causes for decreasing testosterone levels include oophorectomy or 
hysterectomy and treatment with estrogen or corticosteroids. Contrary to men, there is no 
clearly defined condition caused by androgen deficiency (such as hypogonadism in men) 
(42). Moreover, there is no testosterone level below which the level in women is defined as 
low. The guidelines on Androgen Therapy in Women by the Endocrine Society have therefore 
recommended against diagnosing healthy women with an androgen deficiency syndrome 
(42). Information on symptoms related to low testosterone levels and also the prognostic 
implication is sparse. Some studies have shown correlations between low testosterone and 
SHBG levels with decreased bone mineral density, impaired cognitive function, depressive 
symptoms, insulin resistance and surrogate markers of CVD similar to the effects in men (13, 
35, 42). These observations do, however, need to be confirmed in larger cohorts. 
Cardiovascular disease and dysglycemia
In this thesis, testosterone is studied in the context of CVD and diabetes, two conditions that 
are associated with increased mortality per se but also in this regard interlinked. Much is 
known about the background of these conditions as well as their prognostic implications but 
there are still gaps in knowledge attracting interest to further explore the role of testosterone. 
Cardiovascular disease
CVD is the leading cause of mortality worldwide, accounting for 31% of global deaths in 2016 
(43). In Europe, CVD was the reason for 45% of all deaths in 2017 with age-standardized 
rates greater in males than in females (44). CVD is also the most common cause of premature 
death (age <70 years) in European males whereas in females cancer is a more common cause 
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of death (45). The number of people living with CVD is steadily increasing due to longer life 
expectancy combined with a decreasing mortality not the least after myocardial infarction. 
Apart from improved treatment of coronary artery disease (CAD) and a subsequently better 
survival, other reasons for the increasing incidence of CVD are related to dietary habits and 
a more sedentary lifestyle leading to an accumulation of CV risk factors such as obesity, 
hypertension and dysglycemia (46). 
CVD is defined as a group of disorders affecting the coronary, cerebral and peripheral arteries, 
which are often caused by atherosclerosis (47). Atherosclerosis can lead to thickening and 
stiffening of the arterial walls, which may impair the blood flow due to luminal obstruction 
(48, 49). If the obstruction causes a mismatch between oxygen supply and oxygen demand 
in the myocardial tissue, it may lead to ischemia presenting as stable angina pectoris or an 
acute coronary syndrome (ACS) (48). ACS relates to a critical phase of CAD and describes 
a spectrum of clinical manifestations characterized by chest pain, release of troponins and 
presence of electrocardiographic changes. The different manifestations are defined as unstable 
angina, non-ST-elevation myocardial infarction and ST-elevation myocardial infarction (48), 
the last two defined as an acute myocardial infarction (AMI). 
Several factors may contribute to the development and progression of atherosclerotic heart 
disease such as inflammation, dysplipidemia and hyperglycemia (50). Male sex has long been 
considered a risk factor for CVD since the prevalence in CAD is generally higher in men 
than in women as well as the CV mortality rate (51). However, there are gaps in knowledge 
regarding through which mechanisms the risk factors act. Hormones may contribute and 
androgens are of particular interest given the gender differences already described. 
Testosterone and cardiovascular disease in men 
In addition to its effects on reproductive organs, testosterone has been linked to CV surrogate 
markers such as dyslipidemia, insulin resistance and inflammation (Figure 4) (29). It has 
also been hypothesized that testosterone may be directly associated with the development 
of CVD. Indeed, testosterone levels are reported as lower in men with CAD than in those 
without. The prevalence of low testosterone in men with CAD ranges widely, between 17 
and 43% (52-55). 
Low levels of testosterone does not only seem to be common among men with CVD, they 
have also been related to impaired CV prognosis and increased CV and all-cause mortality, 
in men with established CVD (55) and in the general population (15, 26, 29). In the European 
Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) study low total testosterone 
was related to increased risk of CV and all-cause mortality in 2 314 men followed for seven 
years (56). Furthermore, the Osteoporotic Fractures in Men (MrOS) study in which elderly 
men (n=2 416) were followed for five years found that total testosterone in the highest quartile 
was associated with a lower risk of major CV events compared to the lower quartiles (57). 
While a majority of the observational studies have reported an inverse correlation between 
testosterone levels and CV prognosis and all-cause mortality, other investigations reported 
on the opposite relation or no relation at all (58-60). A meta-analysis from 2010 comprising 
19 studies on testosterone and CVD showed no association between testosterone and CVD 
in middle-aged men and only a weak association in elderly men (61). Shortly thereafter 
another meta-analysis was published in 2011, comprising 11 community-based studies of 
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men with all-cause mortality (n=16 184) and seven studies with CV mortality (n=11 831) as the 
primary endpoint (whereof six studies were the same as in the previous analysis). This meta-
analysis showed that low total testosterone was related to both all-cause and CV mortality with 
a stronger relation in older men (62). The conflicting results in observational studies including 
the two meta-analyses may be related to differences in baseline comorbidities or differences 
in analytic methods and thresholds. Furthermore uncertainties in when testosterone should 
be assessed following an acute illness, in the light of that levels decrease following critical 
conditions, is unclear. 
Dysglycemia
Dysglycemia is a term used to describe abnormal blood glucose levels, such as type 2 diabetes 
mellitus type 2 (T2DM) and prediabetes (comprising impaired glucose tolerance test (IGT) 
and impaired fasting glucose (IFG)). Diabetes is defined as a group of disorders characterized 
by hyperglycemia as a result of deficient insulin production, secretion and/or action (63, 64). 
The characteristics are outlined in Table 3. T2DM is the most common type accounting for 
>90% of all people with diabetes. 
Figure 4. Association between low testosterone and cardiovascular risk factors. 
The association between low testosterone levels and CV risk factors have been suggested to be 
potential mediators by which testosterone is related to cardiovascular and all-cause mortality. 
Adapted from Gencer et al. with permission (29). 
Table 3. Main types of dysglycemic disorders (65).
Diagnosis Characteristics
Type 1 diabetes mellitus Autoimmune destruction of pancreatic β-cells leading to an absolute 
insulin deficiency.
Type 2 diabetes mellitus Deficient insulin secretion in the context of increasing insulin resistance. 
Gestational Diabetes Hyperglycemia developed during pregnancy, probably due to increased 
insulin resistance.  
Other specific types of 
diabetes
Genetic defects in β-cells, disease in the exocrine pancreas, surgery of 
the pancreas, drug induced diabetes.
Prediabetes Hyperglycemic conditions at risk of developing diabetes and CVD
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Diabetes, and more specifically T2DM, is increasing rapidly around the world, in part 
explained by increased longevity but also dietary changes and physical inactivity (66). 
According to the International Diabetes Federation, it is the seventh most common cause 
of global mortality. Approximately 463 million adults (20-79 years) had known diabetes in 
2019 with an estimated increase to 700 million by 2045 (66). In addition, about 374 million 
people have IGT. The risk of developing T2DM in individuals with IGT or IFG five years 
after receiving diagnosis is 26 and 50% respectively (67). It has been estimated that in the 
absence of any interventions, 90% of the people with prediabetes will progress to T2DM 20 
years after the diagnosis (68). 
The diagnosis of dysglycemia is determined by using one or more of four diagnostic tests; 
fasting plasma glucose, two-hour post load glucose from an oral glucose tolerance test 
(OGTT), glycated haemoglobin (HbA1c) or random plasma glucose (Table 4).  
People with T2DM are, compared to those free from this condition, more prone to develop 
CVD such as AMI and have a more dismal prognosis if they do (71-73). About half of the 
mortality among patients with T2DM is related to CVD (66, 74). Among patients with AMI, 
approximately 20-25% have known diabetes and of those without known dysglycemia, 
one third is diagnosed with diabetes and one third with IGT when tested with OGTT (72). 
There are still gaps in knowledge regarding how dysglycemia is related to CVD (75, 76). 
Hyperglycaemia and/or traditional CV risk factors such as obesity and hypertension cannot 
provide a full explanation. Hence, other factors related to glucometabolic disorders may be 
of importance in this aspect and further investigations of potential risk factors and/or risk 
markers may explain the relation between dysglycemia and CVD.
Testosterone and dysglycemia in men 
As outlined in Table 1 testosterone is potentially involved in glucose metabolism. Low levels 
have been associated with insulin resistance in observational studies and the relation is likely 
bidirectional (Figure 4) (77). Testosterone levels are lower in men with T2DM compared 
to their healthy counterparts and the prevalence of low testosterone is higher (25-40% vs 
Table 4. Diagnostic criteria and classification of dysglycemia according to the WHO guidelines from 
2006 and 2011 (69, 70). 
Diagnostic criteria
Fasting glucose 
(mmol/L)*
2h-plasma 
glucose 
(mmol/L)*
HbA1c 
(mmol/mol)*
Random plasma 
glucose (mmol/L)
Diabetes Mellitus ≥7.0 ≥11.1** ≥48 Symptoms + ≥11.1
Impaired glucose 
tolerance <7.0 7.8-11.0** -
Impaired fasting 
glucose
6.1-6.9 - -
*should be repeated twice and may be measured in venous or capillary blood. **denotes cut-off for 
venous blood samples. Fasting glucose should be measured from after eight hours of fasting. Two hour 
plasma glucose should be measured from two hours after ingesting a standardized 75 g glucose load. 
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12-34%) in those with T2DM (77-79). In a cross-sectional study comprising 355 men with 
T2DM, 20% had total testosterone levels ≤8 nmol/L, 31% had levels between 8.1-12 nmol/L 
(borderline deficiency), and 50% had low free testosterone levels (<0.26 nmol/L) (80). The 
reduction in testosterone has been partly attributed to altered SHBG levels in patients with 
diabetes (81, 82). However, free testosterone is also considerably lower in males with T2DM 
(83, 84) suggesting that the reduction is not entirely related to SHBG levels.
Men with T2DM and low testosterone seems to have a more dismal prognosis than those 
with normal testosterone. Muraleedharan et al showed that in 581 men with T2DM of whom 
40% had total testosterone ≤300 ng/dl, low testosterone was related to increased all-cause 
mortality (85). In an observational cohort study by Tint et al, low levels of free testosterone 
and high levels of SHBG predicted all-cause mortality during 7.6 years of follow-up in men 
with T2DM (n=531) (86). 
Testosterone, cardiovascular disease and dysglycemia in women
Investigations of sex hormones in women have traditionally put estrogen in focus. As 
described above, testosterone also plays a pivotal role in females both as a precursor for 
estrogen biosynthesis and for exerting androgen effects (13, 87). Whether androgens also 
affect the CV system in women have not been clearly established and it is far less studied 
than in men. Studies have been conducted in women with polycystic ovarian syndrome 
(PCOS), a condition typically characterized by hyperandrogenism (high testosterone levels) 
and hyperinsulinemia. For example, an observational study comprising 21 470 women with 
PCOS followed for a median of five years found an increased risk of T2DM (88). 
Differences in sex hormones between men and women with T2DM have been described, 
for example showing that high testosterone in women but low testosterone in men was 
associated with higher risk of T2DM (89). In a study following women with PCOS for 31 
years, there was no difference in morbidity or mortality from CAD compared to the control 
group (90). Similar to findings in men there are observational studies showing that low levels 
of testosterone are associated with CVD and all-cause mortality in women (87, 91, 92). 
Evidently, the relationship between testosterone and CVD in women is complex and even 
more so in hyperinsulinemic conditions e.g. PCOS. To what extent testosterone is associated 
with an impaired survival in a dysglycemic population remains to be clarified. 
Gaps in knowledge
In summary, available data favours the assumption that there is an association between 
testosterone, CVD and dysglycemia both in men and women. The results are however 
inconsistent, especially in individuals already afflicted with CVD and dysglycemia. The 
dynamics of testosterone levels, prevalence of low testosterone and prognostic implications 
of testosterone in men and women with different stages of dysglycemia and CVD need further 
clarification. Analyses of different fractions of testosterone, i.e. total and free testosterone 
and the binding protein SHBG, as well as the CAG repeat length which is associated with 
androgen receptor responsiveness are of particular interest. Such studies have the prerequisite 
to add a piece to the puzzle explaining this complex relationship and possibly be helpful in 
the search for high-risk individuals.
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AIMS
The overall aim was to study the role of testosterone in men and women with different levels 
of dysglycemia and CVD by investigating:
1) the dynamics of testosterone levels up to a year following an AMI in men with and 
without dysglycemia (Study I)
2) the relation between CAG repeat length, testosterone levels and prognosis (Study II)
3) the prognostic implications of total testosterone, free testosterone and SHBG 
in patients with AMI compared to healthy controls and in men and women with 
dysglycemia and high CV risk (Studies I, III and IV)
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MATERIAL AND METHODS
This thesis is based on four different patient populations derived from a cohort study and a 
clinical trial as summarized in Table 5.
 
Table 5. Overview of the present study cohorts that form the basis of this thesis.
Study I II III IV
Original studies
Cohort name GAMI ORIGIN
Original study design
Observational Randomized controlled trial,  
Biomarker substudy 
Number of study 
subjects
Patients=181
Controls=184
12 537 whereof 8 494 participated in 
the biomarker substudy
Present studies
Present study design Observational Observational Observational Observational
Number of study 
subjects
Patients: 123 males
Controls: 124 males
Patients: 121 males 5 553 males 2 848 females
Mean age at 
inclusion (years)
Patients: 61
Controls: 63
61 64 64
Recruitment years 1998-2002* 1998-2000** 2003-2005 2003-2005
Dysglycemia category 
(%)
Patients: 
36% normal, 
64% IGT or DM
Controls: 
62% normal, 
38% IGT or DM
35% normal, 
65% IGT or DM
80% known DM
7% newly detected 
DM
13% newly 
detected IGT/IFG
84% known DM
5% newly 
detected DM
11% newly 
detected IGT/IFG
Median follow-up 
period (years)
Patients: 11.6
Controls: 10.4
11.6 6.2 6.1
Outcomes CV events, 
CV mortality, 
all-cause mortality
CV events, 
CV mortality, 
all-cause mortality
CV events, 
all-cause mortality
CV events, 
all-cause 
mortality
Number of CV 
events/mortality
Patients:
CV events 50
CV mortality 25
Controls:
CV events 27
CV mortality 12
CV events 50
CV mortality 25
CV events 1 028 CV events 377
Number of all-cause 
deaths
Patients: 38 
Controls: 21
37 951 389
*Recruitment years for patients and controls. **Recruitment years for patients only. CV: cardiovascular; DM: dia-
betes mellitus; GAMI: Glucose in Acute Myocardial Infarction study; IFG: impaired fasting glucose; IGT: impaired 
glucose tolerance; ORIGIN: Outcome Reduction with an Initial Glargine Intervention trial.
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Study populations and design
Studies I and II
Hypotheses
In male patients with AMI with or without dysglycemia: 
Study I
1) Low testosterone levels are common 
2) The testosterone levels vary at different time points after the AMI 
3) The testosterone levels have a prognostic implication.
Study II
1) CAG repeat length is associated with the testosterone levels and cardiometabolic risk factors 
2) CAG repeat length has prognostic implications 
Study cohorts
Studies I and II are based on the observational Glucose Tolerance in Patients with Acute 
Myocardial Infarction (GAMI) study (72). GAMI comprised 181 AMI patients (males 69%) 
without previously diagnosed diabetes and admission capillary glucose <11.1 mmol/L who, 
outside weekends and holidays, were admitted to the coronary care units at Karolinska University 
Hospital Solna and Västerås Hospital 1998 - 2000. People >80 years of age and those with a 
serum creatinine ≥200 µmol were excluded. Patients had fasting blood samples drawn at four 
time points: on the day after admission, at hospital discharge and three and 12 months thereafter. 
An OGTT was performed before hospital discharge in all but 13 patients (2 patients died during 
the hospital stay; 7 due to severe illness, 2 refused to participate, 2 due to technical problems). 
Age- and gender matched controls (n=185; males 69%) without diabetes and CVD (apart 
from well-controlled hypertension) were randomly selected and recruited from the population 
in the recruitment areas between 2001-2002. Five age- and gender matched subjects for each 
patient were randomly selected as possible controls. Control subjects had blood samples 
drawn and performed an OGTT at one occasion (96). 
Blood samples were stored at -70°C pending analyses. Study I comprised all male study 
participants with blood samples available for testosterone analyses at baseline (123 patients 
and 124 controls). Study II comprised all male patients with frozen whole blood samples 
available for DNA extraction (n=122). 
Follow-up and outcomes 
Patients and controls were followed until December 31 2011, resulting in a median follow-
up time of 11.6 and 10.4 years respectively (97). The primary endpoint was a composite 
of major CV events (first occurrence of CV death i.e. death from AMI, stroke, aortic 
dissection or sudden death without obvious reasons; nonfatal AMI; nonfatal stroke; severe 
heart necessitating hospitalization). The two secondary endpoints were CV mortality and 
all-cause mortality. Information on CV events was prospectively collected using hospital 
records for diagnosis and medical interventions. Information on mortality was collected from 
the Swedish National Death Registry and the cause of death in the death certificates were 
validated against available hospital records by the study investigators. In total, one patient 
and one control were lost to follow-up. 
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Studies III-IV
Hypotheses
In individuals with dysglycemia and high CV risk: 
 
Study III
Low levels of total and free testosterone as well as SHBG levels are associated with CV 
events and all-cause mortality in males. 
Study IV
Low levels of total and free testosterone as well as SHBG are associated with CV events and 
all-cause mortality in females.
Study cohorts
Studies III and IV are based on the randomized Outcome Reduction with an Initial Glargine 
Intervention (ORIGIN) trial (94, 98). Individuals ≥50 years with newly detected IFG, 
IGT or diabetes based on an OGTT or known T2DM on stable therapy without or with 
one oral glucose-lowering medication and high CV risk were recruited from 578 clinical 
sites in 40 countries during September 2003 to December 2005. In total, 12 537 participants 
were enrolled and randomized in a 2x2 factorial design to either insulin glargine (Gla-100) 
targeting a fasting plasma glucose ≤95 mg/dl (5.3 mmol/L) or standard care, and omega 3 
fatty acids or placebo.
High CV risk was defined as confirmed evidence of at least one of 
1. Prior AMI, stroke or revascularization
2. Angina with documented ischemia
3. Morning urinary albumin/creatinine ratio >30µg/mg
4. Evidence of left ventricular hypertrophy
5. ≥50% stenosis of a coronary, carotid, or lower extremity artery documented angio-
graphically
6. An ankle/brachial index <0.9 
Main exclusion criterion was use of, indication for or intolerance to insulin or omega 3 fatty 
acids. Patients provided medical history, filled out questionnaires (Figure 5) and fasting 
blood samples were drawn at the baseline visit.
A total of 8 494 (68%) of the ORIGIN participants consented to the collection and storage of 
blood samples for future studies (99). These were obtained at baseline after an overnight fast, 
divided into aliquots and subsequently stored in nitrogen vapour-cooled tanks at –160°C. 
After completion of the ORIGIN trial, coded aliquots of serum were transported to Myriad 
RBM Inc (Austin, Texas, USA) for further analyses. 
Study III comprised all male participants (n=5 553) and Study IV all female participants 
(n=2 848) from the biomarker substudy regardless of treatment allocation.
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Follow-up
Patients were followed for a median of 6.2 years in Study III and 6.1 years in Study IV. The 
primary outcome in Studies III and IV was a composite of major CV events (incident CV 
death and nonfatal AMI) while all-cause mortality served as a secondary outcome. In addition, 
an expanded primary outcome including a revascularization procedure or hospitalization for 
heart failure was studied in Study III. All outcomes were ascertained at every visit based on 
provided information and supporting documentation as well as adjudicated by an adjudication 
committee whose members were unaware of participant allocation. The primary outcome 
was known in 12 443 (99%) of the participants in the main study (98).
Figure 5. Questionnaire for women in the ORIGIN trial.
Centre # Participant #
ORIGIN Trial
Participant ID#
F M L
Initials
Version 4.0 - July 30, 2003
O R I G I N  P2 1 V1
Yes
FOR WOMEN ONLY (please ask the following)
4.
No
Yes
Why did they stop?
(check one)
At what age did they stop? years
Yes
Estrogen aloneWhich type of replacement have you used the most?
How long? years
Estrogen + Progesterone
5.
Unknown
No Are you still 
Age
stopped:
9.
Yes
1.
No
Yes
6.
No
7.
10.
(not including pregnancy)
How was InsulinPills Diet alone
No
Unknown
taking them?
years
Unknown
8.
a) Age at which your 1st child was born?
b) Age at which your last child was born?
What contraception are you currently using?
Radiation/Chemotherapy
Hysterectomy
Other (specify) 
Menopause
Not sexually active Tubal ligation
Oral contraceptives
None
Barrier method 
Other (specify) 
IUD
(birth control pill)
11.
(If one or more)
Partner Vasectomy/sterile
2.
3.
No Yes
No Yes
Have you ever been diagnosed with diabetes during a pregnancy?
Have you ever been diagnosed with pre-eclampsia (pregnancy induced hypertension)?
Have you ever been diagnosed with eclampsia (pregnancy induced severe hypertension)?
Have your menstrual periods stopped permanently?
Have you ever used female hormone replacements for reasons other than birth control?
Have you had a hysterectomy (removal of the uterus)?
Have you had a bilateral oophorectomy (removal of both ovaries)?
Have you ever tried unsuccessfully for a full year or more to become pregnant?
Have you ever used fertility drugs?
Between the ages of 18 and 45 have you ever had 6 or less 
How many children have you given birth to?
Age at
Surgery
menstrual cycles per year?
Medical History: Women Only
→ → Did the diabetes go awayafter the pregnancy?this treated?
No
Yes
→
→
→
→
→
→
→
→
→
→
→
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Definitions
Dysglycemia
In Studies I and II, diabetes and IGT were defined according to the WHO definition from 
1998 based on an OGTT with 75 g of glucose in 200 ml water (93). Patients were categorized 
as having normal glucose tolerance (NGT: 2-hour post-load glucose <7.8 mmol/L) or 
abnormal glucose tolerance (AGT) which comprised diabetes (2-hour post-load glucose 
>11.0 mmol/L) and IGT (2-hour post-load glucose 7.8-11.0 mmol/L). 
In Studies III and IV, dysglycemia was defined as IFG (FPG 6.1-6.9 mmol/L), IGT (2-hour 
post-load glucose 7.8-11.0 mmol/L) or newly detected diabetes (2-hour post-load glucose 
>11.0 mmol/L) after an OGTT with 75 g oral glucose load or known T2DM on stable therapy 
without or with one oral glucose lowering medications for ≥3 months (94). 
Low testosterone levels
Low total testosterone levels were defined as ≤300 ng/dl (=10.4 nmol/L) in Studies I-III, 
in line with guidelines from the Endocrine Society published in 2010 (18). Since there is no 
established cut-off for free testosterone, the threshold used in Studies I-III was ≤7 ng/dl 
(=0.2 nmol/L), based on <2.5th percentile in a community-based sample of men  (95). 
Free testosterone 
Free testosterone was calculated using the Vermeulen formula, assuming an albumin constant 
set at 43 g/L (Figure 6) (20).
Figure 6. Free testosterone calculation by means of the Vermeulen formula.
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Laboratory investigations
Studies I-II
Oral glucose tolerance test
A standardized OGTT with 75 g of glucose dissolved in 200 ml of water was performed 
during stable conditions (day 4 or 5) following a 12 hour overnight fasting at the local 
hospital and for controls at the baseline visit. The glucose levels were measured at 0, 60 
and 120 minutes. 
Testosterone 
Testosterone was extracted from serum using solid phase extraction and determined by high 
performance liquid chromatography-mass spectrometry. The linear range was 1.0–1000 ng/dl 
(r>0.9995) with lower limit of sensitivity at 1ng/dl and the inter-assay coefficient of variation 
was <7%. The analyses were performed at Brigham Research Assay Core at Brigham and 
Women’s Hospital in Boston, USA.
LH and SHBG
LH and SHBG were assessed using solid phase sandwich enzyme-linked immunosorbent 
assays (ELISA), Human LH ELISA (BQ Kits, San Diego, CA, USA) and Human SHBG 
Quantikine ELISA (R&D system, Abingdon, UK). The sensitivity for the LH assay was 1 
mIU/ml and intra- and inter-assay coefficient of variation was 5.0% and 8.4%, respectively. 
The sensitivity for the SHBG assay was 0.5 nmol/l and intra- and inter-assay coefficient of 
variation was 4.9% and 9.9% respectively. 
CAG repeat length
Genomic DNA was extracted using QIAamp DNA Mini Kit from peripheral whole 
blood samples and the CAG repeat length was amplified from genomic DNA using PCR. 
For amplification, the following published primers flanking the CAG repeats were used: 
5’-FAM6-TCC AGA ATC TGT TCC AGA GCG TGC -3’ and 5’- GCT GTG AAG GTT GCT 
GTT CCT CAT-3’ (100). PCR was performed on a GeneAMP 9700 thermocycler (Applied 
Biosystems), PCR-FAM amplicons were resolved with capillary electrophoresis and 
thereafter identified using an ABI 3730 Genetic Analyzer (Applied Biosystems). By use of 
GeneScanTM- 500LIZ® Size standards (Applied Biosystems) with GeneMapper Software 
(Applied Biosystems) the CAG repeat length was determined. The analyses for LH, SHBG 
and CAG repeat length were performed at ANOVA (Center for Andrology, Sexual Medicine 
and Transmedicine), Karolinska University Hospital, Stockholm, Sweden.
Studies III-IV
Testosterone, LH, SHBG
Sex hormones were measured as part of a prespecified panel by means of the Human 
Discovery Multi-Analyte Profile (MAP) 250+ panel on the LUMINEX 100/200 platforms. 
After careful blinded scrutiny of the results, 237 biomarkers from 8 401 study subjects were 
available for analysis including total testosterone, LH and SHBG with inter-run coefficients 
of variation of 7, 6 and 14% respectively. Analyses were performed at Myriad RBM Inc. 
(Austin, Texas, USA).  
          Testosterone, cardiovascular disease and dysglycemia
27
Statistical analyses
Analyses were performed using SAS statistical software, version 9.4 (Studies I-II, IV) and 
version 9.2 (Study III). The nominal level of significance for all analyses was a two-sided 
p-value of <0.05.
Descriptive statistics
In Study I, continuous variables were presented as median and interquartile ranges and 
categorical variables as numbers and percentages. Differences between groups, e.g. patients 
vs. controls or AGT vs. NGT, were compared using Wilcoxon two-sample test for continuous 
variables (e.g. testosterone levels) and chi-square test for dichotomous variables (e.g. 
prevalence of low testosterone). 
In Study II, the relation between CAG repeat and testosterone as well as selected CV 
risk factors, which were based on clinical relevance and previous studies and include e.g 
different measures of dysglycemia, BMI and CRP, were assessed using Pearson’s correlation 
coefficient. Additionally, CAG repeat length was dichotomized according to the median level 
as >20 vs. ≤20 in the baseline table and analyses on testosterone levels over time by CAG 
group.
In Studies III-IV, continuous variables were presented as mean and standard deviation (SD) 
and categorical variables as numbers and percentages.
Comparison between groups with lower vs. higher hormone levels was assessed using t-test 
for continuous variables and chi-square test for dichotomous variables. 
Survival analyses
In Studies I-II, the relationship between testosterone and CAG respectively with outcomes 
were assessed using Cox proportional hazards regression in univariate and multivariate 
models, presented as hazard ratio (HR) and 95% confidence interval (CI). In Study I, 
analyses by one standard deviation (SD) increment from testosterone samples at the day after 
hospital admission for patients and at the baseline visit for controls were performed. The SD 
was calculated separately for patients and controls. Adjustments were made for smoking, 
body mass index (BMI), SHBG and 2 hour-post glucose load both separately and combined. 
The covariates were selected based on previous studies and clinical relevance (77, 101). 
Model A was unadjusted and Model B was adjusted for smoking, BMI, SHBG and 2-hour 
post-load glucose. In Study II, Cox analyses for CAG repeat length was carried out by 
one unit increment and by CAG group, in unadjusted (Model A) and age-adjusted analyses 
(Model B). 
In Studies III-IV, the prognostic ability of sex hormones (testosterone, free testosterone 
and SHBG) was tested using Cox proportional hazard regression as well as illustrated with 
Kaplan-Meier curves. HR were estimated for one SD increment and by higher vs. lower 
levels (according to total and free testosterone threshold and SHBG median level) in Study 
III. In multivariate models the association between respective hormone and events were 
adjusted for age in Model A and for age, LH levels, previous CVD, previous DM, use of 
metformin, use of statins, systolic blood pressure, HbA1c, low density lipoprotein (LDL) 
cholesterol, BMI and smoking in Model B. The covariates were chosen based on previous 
data and clinical relevance (1, 15).
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HRs of total testosterone, free testosterone and SHBG for prognosis by one SD increment were 
estimated in Study IV. Multivariate adjustments were performed in several models. In Model 
A the respective hormone was adjusted for age. Model B included Model A (age) plus LH 
levels, previous CVD, previous DM, use of metformin, use of statins, systolic blood pressure, 
HbA1c, LDL-cholesterol, BMI and smoking. Model C included Model B plus menopause 
with or without hormone therapy, thyroid hormone treatment, alcohol consumption, ethnicity 
and obstructive sleep apnea. Tests for interaction between total testosterone, free testosterone, 
SHBG, outcomes and study allocation were performed in Studies III and IV. 
Ethical approvals 
All studies agree with the Declaration of Helsinki. Study I had been previously approved by 
the Regional Ethical Board in Stockholm and an additional ethical approval was obtained for 
Study II. Studies III and IV were approved by the local ethics committee at each study site. 
Patients provided written, informed consent prior to participation in the main studies. 
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RESULTS
Study I
Baseline characteristics
The study cohort comprised 123 male patients and 124 male controls. As outlined in Table 6, 
patients had more comorbidities and were more often prescribed cardioprotective drugs. 
Capillary blood glucose, HbA1c and creatinine were higher in patients than controls. Glucose 
categorization at discharge disclosed AGT in 75 patients (64%) compared to 47 (38%) in the 
control group. 
Table 6. Selected baseline characteristics of the study cohort for Studies I and II. 
Continuous variables presented as median (IQR) and categorical variables presented as n (%). 
Study I Study II
Total cohort (n=247) Patients (n=121)
Patients
n=123
Controls
n=124
CAG ≤20
n=68
CAG >20
n=53
Clinical characteristics
     Age (years) 61 (55-71) 63 (56-73) 61 (56-68) 62 (56-73)
     Current smokers 39 (32)* 13 (10)* 19 (28) 19 (36)
     BMI (kg/m2) 26 (24-29) 26 (24-29) 26 (24-29) 26 (24-28)
     Family history T2DM 21 (18) 16 (13) 13 (19) 8 (16)
     Family history IHD 60 (50)* 32 (26)* 38 (57) 22 (42)
Previous disorders
     MI 27 (22)* 0 (0)* 16 (24) 10 (19)
     Hypertension 33 (27)* 20 (16)* 21 (31) 11 (21)
     Hyperlipidemia 18 (15)* 6 (5)* 10 (15) 7 (13)
Pharmacological treatment
     ACE Inhibitor 10 (8) 9 (7) 19 (28) 15 (28)
     β-Blocker 36 (29)* 13 (10)* 7 (10) 3 (6)
     Statins 13 (11)* 3 (2)* 7 (10) 5 (9)
Biochemical characteristics at baseline
     Capillary blood glucose 6.2 (5.6-7.4)* 5.0 (4.6-5.5)* 6.0 (5.4-7.0)* 7.1 (5.9-7.8)*
     HbA1c (%) 4.9 (4.5-5.3)* 4.6 (4.3-5.0)* 4.9 (4.6-5.3) 4.9 (3.8-4.9)
     Creatinine (µmol/l) 96 (86-107)* 84 (78-94)* 95 (86-106) 99 (85-111)
     NGT 43 (36)* 77 (62)* 25 (38) 16 (32)
     Testosterone (ng/dl) 243 (184-346)* 380 (276-476)* 226 (177-334) 265 (207-383)
     Free testosterone (ng/dl) 3.1 (2.2-3.9)* 4.3 (3.6-5.5)* 2.6 (2.0-3.5) 3.2 (2.6-4.3)
     SHBG (nmol/L) 70 (52-93) 71 (51-91) 67 (51-93) 72 (53-92)
     LH (mIU/ml) 2.1 (1.4-3.7) 1.9 (1.1-3.3) 1.9 (1.1-3.1) 2.0 (1.3-3.5)
Prevalence of low      
testosterone 79 (64)* 35 (28)* 47 (69) 30 (57)
* denotes a significant difference (p<0.05) between groups.
Abbreviations: ACE: angiotensin-converting enzyme; BMI: body mass index; IHD: ischemic heart disease; LH: 
Lutenizing hormone; MI: myocardial infarction; N/A: Not applicable; NGT: Normal Glucose Tolerance; SHBG: Sex 
hormone-binding globulin; T2DM: type 2 diabetes
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Testosterone levels over time
Total testosterone levels on the day after admission were lower in patients than in controls 
(243 ng/dl vs. 380 ng/dl; p<0.01) but the levels had increased at the time for hospital discharge 
to a median testosterone of 311 ng/dl and further to 345 ng/dl after three and 357 ng/dl after 
12 months (Figure 7A). The levels of free testosterone were lower at admission (3.1 ng/
dl) but increased to a similar level (3.5, 4.2, 4.3 ng/dl respectively) as that observed among 
controls (4.3 ng/dl) over time (Figure 7B). 
The total testosterone/LH ratio (TT/LH) was 115.7 in the patient and 200 in the control 
cohort at the first time point. At the following time points TT/LH was 163.2, 156.8 and 162.3 
respectively. The free testosterone/LH ratio (FT/LH) in patients was 1.5, 1.8, 1.9 and 1.9 at 
the different time points compared to 2.3 in controls. 
Sixty four percent of the patients had low total testosterone levels (≤300 ng/dl) on the day after 
admission compared to 28% of the controls at baseline (p<0.001; Figure 8). The proportion 
of patients with low total testosterone decreased over time from 46% at hospital discharge, 
to 35% after three and to 30% after 12 months, a prevalence similar to that of the controls. 
In subgroup analyses, the prevalence of low testosterone was higher in patients with AGT 
compared to NGT at the first time point (p=0.002). The difference between testosterone levels 
and prevalence of low testosterone in the two glucose tolerance categories had diminished at 
the time for discharge and thereafter. There was no significant difference between AGT vs. 
NGT group among controls (p=0.05). 
Total testosterone levels were lower in patients with AGT at the first time point, but this 
difference became attenuated over time (Table 7). Among controls, there was no difference in 
testosterone levels between the different glucose categories. Free testosterone levels did not 
differ between patients or controls with AGT and NGT at any of the time points.
Figure 7. Dynamics of total (A) and free (B) testosterone levels over time. Boxes represent 25th–75th 
percentile, band inside box median and whiskers range. The dashed line in panel A represents the 
threshold for low testosterone levels (≤300 ng/dl). 
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Figure 8. Prevalence of low testosterone (≤300 ng/dl) over time in all patients and by glucose category.  
NGT: normal glucose tolerance; AGT: abnormal glucose tolerance. n.s.: not significant. * denotes 
significant difference between the NGT and AGT group.
Table 7. Total and free testosterone levels (ng/dl) for patients and controls by glucose category. 
The testosterone levels are presented as median and interquartile range (IQR). P-value denotes 
significance level in testosterone between NGT/AGT. 
Patients Controls
Day after 
admission
(n=118)
Discharge
(n=113)
3 months
(n=98)
12 months
(n=84)
Baseline
(n=124)
NGT n=43 
AGT n=75
NGT n=42 
AGT n=71
NGT n=36 
AGT n=62
NGT n=34 
AGT n=50
NGT n=77
AGT n=47
Total testosterone
NGT 308 (199-387) 349 (236-497) 342 (231-452) 363 (270-505) 386 (315-481)
AGT 230 (178-301) 306 (188-408) 352 (284-428) 357 (269-450) 341 (266-441)
p 0.04 0.09 0.81 0.79 0.15
Free testosterone
NGT 3.2 (2.2-4.2) 3.6 (2.8-4.5) 4.2 (3.2-5.5) 4.5 (3.4-5.6) 4.3 (3.7-5.5)
AGT 3.0 (2.1-3.6) 3.4 (2.0-4.6) 4.2 (3.2-5.0) 4.4 (3.5-5.4) 4.1 (3.2-5.2)
p 0.18 0.35 1.00 0.69 0.28
Abbreviations: AGT: Abnormal glucose tolerance; NGT: Normal glucose tolerance.
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Survival analyses
Patients and controls were followed for a median time of 11.6 and 10.4 years respectively. In 
patients, an increment by one SD of total testosterone at admission (SD=163.4 ng/dl; Figure 
9A) did not predict any of the studied outcomes. In unadjusted analyses (Model A), one SD 
increment of free testosterone (2.93 ng/dl) predicted the primary CV endpoint in patients (HR 
1.23; 95% CI 1.02-1.49; p=0.03). This association remained after univariate adjustments for 
post-load glucose but not following univariate adjustments for SHBG, BMI and smoking 
separately or in the multivariate model (Model B). 
In controls, an increment by one SD of total testosterone (SD=153.1 ng/dl) was associated 
with reduced risk of CV death by 52% (HR 0.48; 95% CI 0.25-0.94; p=0.03) but did not 
influence the other endpoints in unadjusted analyses (Figure 9B). Total testosterone remained 
a significant predictor for CV and total mortality after multivariate adjustments (Model B). 
Furthermore, free testosterone in controls (SD=1.99 ng/dl) was associated with lower CV and 
total mortality, in unadjusted (Model A) as well as adjusted analyses (Model B) (Figure 9B). 
Figure 9. Total and free testosterone in patients (Figure A) and controls (Figure B) by increment of 
one standard deviation with regards to cardiovascular (CV) events, CV mortality and total mortality. 
Model A: Unadjusted
Model B: Adjusted for BMI, smoking, post-load glucose level and SHBG. 
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Study II
Baseline characteristics
In total 121 patients had samples available for CAG characterization. In Table 6 baseline 
characteristics are presented for the study cohort dichotomized into those below or above 
the median CAG level (CAG ≤20 and CAG >20). The CAG ≤20 group had lower capillary 
blood glucose at admission compared to the CAG >20 group (6.0 vs 7.1 mmol/L; p=0.0016), 
otherwise the two groups were similar in all the described aspects including age, previous 
medical history and testosterone levels.
CAG repeat, testosterone and cardiovascular risk factors
The median CAG repeat length was 20 (range 13-26). There was no significant difference in 
median testosterone levels or in the prevalence of low testosterone between the CAG ≤20 and 
CAG >20 groups as outlined in Table 8 and Figure 10.
Table 8. Sex hormone levels (ng/dl) in relation to CAG repeat group in the study population. 
P-value denotes significance level in testosterone between CAG group.
Total testosterone (ng/dl)
Day after 
admission (n=121)
Discharge
(n=113)
3 months  
(n=99)
12 months 
(n=85)
CAG ≤20 226 (177-334) 269 (204-415) 345 (261-427) 352 (270-437)
CAG >20 265 (207-383) 369 (212-471) 359 (298-456) 393 (287-512)
p 0.12 0.08 0.29 0.13
Figure 10. Prevalence of low testosterone (≤300 ng/dl) over time in patients with CAG ≤20 
and >20. n.s.=not significant difference. 
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CAG repeat length in the cohort as a whole did not correlate to the CV risk markers studied, 
i.e. capillary blood glucose, HbA1c, glucose category, CRP or creatinine and not to the sex 
hormones i.e testosterone,  free testosterone, SHBG or LH (Table 9).
Survival analyses
Patients experienced 50 CV events and 37 all-cause deaths whereof 25 (68%) died from 
CV causes during the follow-up of 11.6 years. More patients in the CAG >20 group died 
from all causes (42 vs. 22%; p=0.02) while there was no difference in proportion of 
events between the two groups for CV events and mortality. CAG repeat length was not 
associated with any of the endpoints in unadjusted and age-adjusted Cox analyses by one 
unit increment (Figure 11A). When analyzed as a below/equal to vs above median (=20), 
CAG repeat length was not associated with any CV outcomes. CAG >20 was related to 
increased all-cause mortality in unadjusted analyses but this association was attenuated in 
the age-adjusted analyses (Figure 11B). 
Table 9. Pearson’s Correlation for the association between CAG repeat length and cardiometabolic 
risk factors. 
CAG repeat length
Variables r2 p
     BMI (kg/m2) -0.06 0.50
     CRP (mg/L) 0.12 0.20
     Capillary blood glucose (mmol/L) 0.13 0.16
     HbA1c (%) -0.05 0.57
     Creatinine (µmol/L) 0.03 0.77
     Normal glucose tolerance (%) -0.002 0.99
     Testosterone (ng/dl) 0.14 0.12
     Free testosterone (ng/dl) 0.07 0.41
     Prevalence of low testosterone (%) 0.10 0.27
     SHBG (nmol/L) 0.13 0.17
     LH (mIU/ml) -0.02 0.82
BMI: Body Mass Index; CRP: C-reactive protein; HbA1c: Glycated haemoglobin; LH: 
Luteinizing hormone; SHBG: Sex hormone-binding globulin
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Study III
Baseline characteristics
The cohort in Study III comprised 5 553 men (mean age 63.5 years) whereof 80% with 
previously diagnosed diabetes and the remainder with newly detected diabetes, IFG or IGT 
(Table 10). There was a high prevalence of previous CVD (including myocardial infarction, 
stroke and coronary, carotid or peripheral artery revascularization) and hypertension. 
Figure 11. CAG repeat and cardiovascular (CV) events, CV mortality and all-cause mortality by 
increment of one unit (A) and dichotomized to > median vs. ≤ median (B).
Model A: Unadjusted
Model B: Adjusted for age
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Frequently prescribed pharmacological treatments included statins and angiotensin-
converting enzyme/angiotensin receptor II blocker (ACE/ARB) inhibitors. The mean (SD) 
of total and free testosterone levels were 416.6 (109.2) ng/dl and 8.4 (3.2) ng/dl, and 13% 
had low total testosterone ≤300 ng/dl) and 37% low free testosterone (≤7 ng/dl). The median 
(IQR) SHBG was 35 (25–47) nmol/L. Individuals with SHBG levels above median had 
lower free testosterone levels (6.7 vs 10.0ng/dl; p<0.001) and higher LH level (3.0 vs 2.5 
mIU/ml; p <0.001).
Table 10. Selected baseline characteristics of the study cohort in Studies III-IV. Continuous variables 
are presented as mean (SD) and categorical variables as n (%).
STUDY III STUDY IV
Males
n=5 553
Females 
n=2 848
Clinical characteristics
     Age (years) 63.5 (7.9) 64 (8)
     Known diabetes 4441 (80.0) 2399 (84.2)
     Newly detected diabetes 400 (7.2) 150 (5.3)
     Newly detected IFG/IGT 710 (12.8) 298 (10.5)
     Previous cardiovascular disease 3763 (67.8) 1228 (43.1)
     Myocardial infarction 2397 (43.2) 640 (22.5)
     Hypertension 4219 (76.0) 2419 (84.9)
     Smoker 754 (13.6) 296 (10.4)
     Menopause N/A 2086 (73.2)
Pharmacological treatment
     Metformin 1431 (25.8) 886 (31.1)
     Sulfonylurea 1613 (29.0) 810 (28.4)
     Other glucose lowering drug 118 (2.1) 51 (1.8)
     No glucose lowering drug 2394 (43.1) 1101 (38.7)
     Statins 3375 (60.8) 1241 (43.6)
     ACE/ARB inhibitors 3836 (69.1) 1957 (68.7)
     Beta-blockers 3160 (56.9) 1366 (48.0)
Biochemical characteristics
     BMI 29.6 (4.7) 31.1 (6.2)
     eGFR (ml/min/1.73m2) 79.0 (21.4) 74.5 (22.6)
     HbA1C (DCCT %; mmol/mol) 6.5 (0.9); 48 6.6 (1.0); 49
     Cholesterol (mmol/L) 4.7 (1.1) 5.2 (1.2)
     LDL-cholesterol (mmol/L) 2.8 (1.0) 3.1 (1.1)
     Total testosterone (ng/dl) 416.6 (109.2) 122.6 (76.6)
     Low total testosterone 701 (12.6) N/A
     Free testosterone (ng/dl) 8.4 (3.2) 2.2 (1.7)
     Low free testosterone 2035 (36.6) N/A
     SHBG (nmol/L) 35 (25–47)* 44.6 (24.7)
     LH (mIU/ml) 2.8 (1.6) 8.4 (4.1)
* Presented as median (IQR). ACE/ARB: angiotensin-converting enzyme/angiotensin receptor II blocker; BMI: 
body mass index; eGFR: estimated glomerular filtration; HbA1c: glycated haemoglobin; HDL: high-density 
lipoprotein; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; LDL: low-density lipoprotein; LH: 
luteinizing hormone; N/A: Not applicable; SHBG: sex hormone-binding globulin. 
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Survival analyses
During a median of 6.2 years follow-up, 1 028 patients experienced a CV event and 951 
patients died. As outlined in Figure 12A, neither total nor free testosterone were significant 
predictors of events in the multivariable, adjusted models (Model B). An increment of SHBG 
by one SD did, however, predict CV events and all-cause mortality in age- and multivariable, 
adjusted models. In categorical analyses, total testosterone did not predict any of the outcomes. 
Normal compared to low levels of free testosterone was associated with a reduced risk of 
all-cause mortality in models A and B (Figure 12B). SHBG above median was associated 
with an increased risk for CV events as well as all-cause mortality compared to levels at or 
below median (Figures 12B and 13). There was no significant interaction between study 
allocation and total testosterone, free testosterone and SHBG (data not shown). In additional 
analyses of the expanded primary outcome, including revascularization and heart failure 
hospitalizations, none of the sex hormones were significant predictors (data not shown).
Figure 12. Total testosterone, free testosterone and sex hormone-binding globulin (SHBG) with 
regards to cardiovascular (CV) events and all-cause mortality in males by an increment of one 
standard deviation (A) and dichotomized as normal vs. low levels (low testosterone ≤300 ng/dl, low 
free testosterone ≤7 ng/dl and SHBG ≤35 nmol/L) (B). 
CI: confidence interval. 
Model A: adjusted for age. 
Model B: adjusted for age, luteinizing hormone levels, previous cardiovascular disease, previous 
diabetes diagnosis, use of metformin, use of statins, systolic blood pressure, glycated haemoglobin, 
low-density lipoprotein cholesterol, body mass index and smoking. 
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Study IV
Baseline characteristics
A total of 2 848 women of mean age 64 years were included in the study cohort whereof 73% 
were post-menopausal. Known diabetes was found in 84% and newly detected diabetes, IFG 
or IGT in 16% of the total cohort. Previous CVD was reported by 43%, previous myocardial 
infarction by 23% and hypertension by 85%. Cardioprotective drugs including ACE/ARB-
inhibitors and statins were frequently used as outlined in Table 10. 
The mean total and free testosterone levels were 122.6 ng/dl and 2.2 ng/dl respectively. The 
median SHBG was 39 nmol/L. 
Survival analyses
There were 377 CV events and 389 all-cause deaths during a median follow-up period of 6.1 
years. While neither total nor free testosterone were significant predictors of future events, an 
increment by one SD SHBG was associated with all-cause mortality even after adjustments 
(HR 1.14; 95% CI 1.05-1.24; p<0.01) (Figure 14). There was no significant interaction 
between sex hormones, outcomes and study allocation.  
Figure 13 A and B. Kaplan-Meier curves for categorical variables of sex hormone-binding globulin 
(SHBG) (≤35 nmol/l) with regards to cardiovascular events (A) and all-cause mortality (B). Hazard 
ratio (HR) (95% confidence interval (CI)) from the multivariate Cox regression model. 
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Figure 14. Total testosterone, free testosterone and sex hormone-binding globulin (SHBG) by 
increment of one standard deviation with regards to cardiovascular events and all-cause mortality. 
Model A adjusted for age
Model B adjusted for age, LH levels, previous cardiovascular disease, previous diabetes diagnosis, 
use of metformin, use of statins, systolic blood pressure, HbA1c, low-density lipoprotein cholesterol, 
body mass index and smoking.
Model C adjusted for Model B plus menopause and no hormone therapy, menopause and hormone 
therapy, thyroid hormone treatment, alcohol consumption, ethnicity, obstructive sleep apnea.
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DISCUSSION
Summary of the main findings
CVD and diabetes are major contributors to the global health burden. By studying testosterone, 
this thesis aimed at advancing the understanding of why patients with diabetes have an 
impaired CV prognosis. In summary, low testosterone was common in patients hospitalized 
with AMI, in particular in those with AGT, but the levels increased over time. However, and 
in contrast to healthy controls where low testosterone was predictive of prognosis, there 
was no clear association between the testosterone level and the prognosis in people already 
afflicted with CAD. However, the relation seems to be complex as both low free testosterone 
(≤7 ng/dl) and increasing levels of SHBG were associated with prognosis in men with 
dysglycemia and high risk for CVD. SHBG but not testosterone was related to prognosis in 
women. A variable of potential interest in the relation between testosterone and CVD, CAG 
repeat length, did not seem to be of importance in men with AMI. 
Low testosterone in cardiovascular disease and dysglycemia
In Study I, investigating the dynamics of testosterone over time, low total testosterone levels 
were found in 64% of the patients on the day after admission for an AMI. After three and 12 
months, this prevalence (35 and 30%) was similar to that in the control population (28%). 
In Study III, the proportion with low total testosterone was lower, 13%. One of the possible 
explanations to the higher prevalence of low testosterone during the first time point in Study 
I is that the samples were acquired during the early phase of an AMI. As described in the 
introduction, the Endocrine Society guidelines recommend against diagnosing testosterone 
deficiency in men recovering from acute illness since the levels may be influenced by stress 
(18, 23). Similar to the findings in Study I, previous investigations of the dynamics of 
testosterone in small groups of AMI patients (n=13-30) showed a reduction of testosterone in 
the acute phase (102, 103). Less is known about the levels after discharge. In a case-control 
study by Pesonen et al. including 264 males with ACS, a high prevalence of low testosterone 
levels (around 44%) was shown within five days of hospitalization (60). In similarity to the 
findings in Study I, the levels had increased to comparable levels as measured in controls 11 
months after the acute event. A clear definition of an appropriate time for accurate testosterone 
assessment following acute illness is missing in available guidelines. The observations from 
Study I suggest that testosterone may be assessed about three months after an AMI, but the 
results should be validated in another cohort before a strong recommendation is made.
The reasons for decreased testosterone levels during ACS is not fully understood but acute 
critical illness is known to affect the HPT-axis leading to a fall in testosterone (12). LH 
concentrations may be normal or slightly elevated in the setting of acute illness, which also 
suggest a peripheral resistance during stress. LH levels in patients in Study I were rather 
constant at all time points whereas testosterone levels varied. Other factors that may contribute 
to low testosterone levels are comorbidities increasing the susceptibility to stress such as 
diabetes. Interestingly, during the acute phase of the AMI in Study I, the prevalence of low 
testosterone was higher in those with dysglycemia compared to those without (75% vs. 47%). 
However, the difference in testosterone levels between dysglycemic and normoglycemic 
individuals was attenuated over time. The findings could relate to dysregulation of the HPT-
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axis following insulin resistance, which is augmented during the early stage of an AMI (77, 
104). In animal and in-vitro studies, insulin action and responsiveness have been related to the 
function of the HPT-axis (79, 105, 106). Furthermore insulin resistance has been associated 
with changes in Leydig cell function, such as a decreased responsiveness to LH resulting in 
a reduced production and release of testosterone (107). Thus, it may be hypothesized that 
patients with dysglycemia have lower testosterone levels in the acute phase since their HPT-
axis is more sensitive to acute illness due to insulin resistance. 
The prevalence of low testosterone varies greatly in different observational studies, as outlined 
in Table 11, and this may at least partially be attributed to differences in comorbidities such as 
CVD and diabetes. In Study I, the prevalence of low testosterone remained quite high even 
in the more stable phase of CAD in comparison to Study III. The presence of established 
CAD could partially explain this higher prevalence, since although patients were at high CV 
risk in Study III, only 43% had a history of AMI. Furthermore, all men in Study III had 
dysglycemia. This alters the SHBG levels, which may confound the prevalence of a low 
total testosterone. For this reason, the international Endocrine Society have recommended 
measurement of free testosterone in individuals with diabetes to assess androgen status more 
accurately. Indeed, the prevalence of low free testosterone was markedly higher than that of 
total testosterone (37 vs. 13%) in Study III. In line with these results, the prevalence of low 
total testosterone levels was 20-31% in 355 men with T2DM and higher, 50%, with low free 
testosterone (80). These findings underline the importance of assessing free testosterone in 
individuals with dysglycemia as recommended by guidelines. 
Different threshold for low testosterone and assay methods
Another potential explanation for the diverging prevalence of low testosterone in different 
studies is the thresholds (Table 11). In contrast to the prevalence after 12 months (30%) in 
Study I, the prevalence of low total testosterone was around 17% in a prospective study 
investigating 930 men with stable CAD, i.e. similar to the prevalence (13%) in Study III 
(55). The cut-off in that study was however lower (<234 ng/dl) than in Studies I and III 
(≤300 ng/dl) illustrating that many different aspects have to be accounted for and therefore 
preclude direct comparisons between trials. On the other hand, men in the control group 
in Study I had a higher prevalence of low testosterone (28%) than men in Study III. The 
same cut-off but different assay methods was used as described below and this could also 
contribute to a higher prevalence in Study I.
Several studies (Table 11) dichotomize testosterone according to cut-offs provided by 
guidelines for diagnosing hypogonadism or reference ranges provided by their respective 
laboratory whereas other categorize testosterone into tertiles and quartiles. Attempts have 
been made in effort to clarify the cut-off level for total and free testosterone. In 2011, the 
2.5th percentile (by convention used to define the lower limit of the reference range) for total 
testosterone was 348 ng/dl and for free testosterone 7 ng/dl in a community-based sample 
of 1 893 men (95). A more recent study from 2017, aiming at providing a reference range 
generalizable to a wider population, was based on four cohorts from Europe and the United 
States. Based on testosterone measurements performed in healthy, young, non-obese men, 
the lower limit of total testosterone (2.5th percentile) in each cohort which was calibrated 
into a harmonized reference range was 264 ng/dl (108). This cut-off was adopted by the 
most recent Endocrine Society guidelines for total testosterone and applies to when Centers 
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for Disease Control and Prevention certified assays are used (23). If such certified assays 
are not available, the use of reference ranges established by the laboratory in question is 
recommended (18, 23). A harmonized reference range for free testosterone has not been 
established but the cut-off recommended in the guidelines is 5-9 ng/dl (0.2-0.3 nmol/L) (18). 
For this thesis, the threshold ≤300 ng/dl for total testosterone was used based on available 
guidelines (from 2010) at the time of performing Studies I-III. This threshold is frequently 
used in other studies (18, 26). For free testosterone, the cut-off in the community-based study 
from 2011 mentioned above (≤7 ng/dl) was used.
Finally, the discrepancy between studies could be related to the different assays used to analyze 
testosterone. There are two main methods currently in use; 1) liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) which is considered the gold standard and 2) different 
types of immunoassays (1). In Study I, testosterone analyses were performed by LC-MS/MS 
whereas multiplex analyses (a kind of immunoassay measuring a large number of analytes) 
were used in Study III. Due to analytical difficulties and requirement of trained personnel, 
the LC-MS/MS method is used less often in research and clinical practice (Table 11) and 
different types of immunoassay are more frequently found in laboratories around the world 
even if there is a high inter-assay variability and inaccuracy compared to LC-MS/MS. This 
could potentially contribute to the prevalence of low testosterone in Study III being slightly 
less than expected in a population with dysglycemia and CVD. 
Table 11. Prevalence of low testosterone in men, threshold used and assay method of testosterone 
in observational studies. 
Cohort Assay method Prevalence of low 
testosterone
Araujo et al. (37) Population-based cohort 
(n=1691)
Radioimmunoassay 6% at baseline*
12% after 9 years follow-up
Harman et al. (38) Population-based cohort 
(n=890)
Radioimmunoassay 20-30% with TT ≤325 ng/dl
Kapoor et al. (80) Men with T2DM (n=355) ELISA 20% with TT <231 ng/dl
31% with TT 231-346 ng/dl
50% with FT <7 ng/dl
Malkin et al. (55) Men with CAD (n=930) ELISA 17% with TT <234 ng/dl
21% with bio-T <75 ng/dl
Shores et al. (109) Population-based cohort 
(n=1032)
LC/MS 25% with TT ≤278 ng/dl
Hamilton et al. (110) Men with T2DM (n=788) LC/MS 16% with TT <231 ng/dl
30% with TT <288 ng/dl
Pesonen et al. (60) Men with ACS (n=264) and 
healthy controls (n=238)
Radioimmunoassay 44% with TT ≤266 ng/dl
Gencer et al. (111) Men with ACS (n=1054) Electrochemi-
luminescence assay
41% with TT ≤300 ng/dl
Bio-T: Bioavailable testosterone; CAD: Coronary artery disease; ELISA: Enzyme-linked immunosorbent assay; FT: 
Free testosterone; LC/MS: Liquid chromatography/Mass spectrometry; SHBG: Sex hormone-binding globulin; 
T2DM; Type 2 diabetes mellitus; TT: Total testosterone.
* Defined as low TT (<200 ng/dl) + symptoms of androgen deficiency or low-normal TT (200-400 ng/dl) + low FT 
(<8.9 ng/dl) + symptoms of androgen deficiency. 
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Prognostic implications of sex hormones 
Testosterone and SHBG in men
Total testosterone was not a significant predictor of prognosis in men with AMI or at high 
CV risk and with different levels of dysglycemia (Studies I and III) but free testosterone 
below threshold (≤7 ng/dl) was associated with increased all-cause mortality in men from 
the ORIGIN biomarker substudy (Study III). This suggests that total testosterone is of 
questionable importance as a prognostic marker in men already afflicted with CVD and 
dysglycemia, in particular in the setting of acute illness where low testosterone may rather 
be a marker of general disease. It may be argued that the findings in Study I relate to the 
relatively low number of participants but similar results have been reported in a larger cohort 
of patients with ACS. In 1 054 men hospitalized for ACS, total testosterone in blood samples 
drawn during angiography was low (≤300 ng/dl) in 41% of the men and did not predict 
prognosis (111). On the other hand, men with stable CAD (n=930) and low bioavailable 
testosterone levels had an impaired CV survival during seven years follow-up compared 
to those with normal levels (55). Evidently, the association between testosterone and CAD 
seems to be different in acute and stable conditions. 
The relation between testosterone and prognosis is still not fully understood, especially in 
populations with a high proportion of dysglycemia as in Studies I and III. What further 
complicates the interpretation is that several studies have shown impaired prognosis in 
groups both with the lowest and the highest levels, suggesting a U-shaped rather than a 
linear relation between testosterone and prognosis (29, 110, 112). Moreover, the divergent 
results could relate to the fraction of testosterone investigated. As suggested by Oskui et al, 
low free or bioavailable testosterone have generally presented more consistent prognostic 
information than total testosterone, potentially due to the biologically inactive parts of 
total testosterone confounding the impact on prognosis (15). Indeed, low levels of free 
and bioavailable testosterone and/or low SHBG have been associated with impaired CV 
and all-cause survival in men with CVD or T2DM (55, 86, 113-116). In comparison, free 
testosterone ≤7 ng/dl and increasing SHBG levels were related to a reduced risk of CV events 
and all-cause mortality in Study III. The mechanism behind the association is not clear. One 
possible explanation relates to the hypothesis that only free testosterone is biologically active 
(rather than the total volume in plasma) and SHBG which binds testosterone with a high 
affinity modulates the level of free testosterone available (16, 117). Thus, high SHBG could 
indicate low levels of free testosterone in plasma. However, as testosterone levels in blood 
strive to reach equilibrium, it could be that while increasing SHBG can lead to a decrease 
of free testosterone, this triggers the feedback mechanism of the HPT-axis to secrete more 
LH stimulating the testosterone production until levels are restored (16). Interestingly, the 
association between SHBG and outcomes remained significant after adjustment of LH levels 
in Study III. This suggests that SHBG may have independent and unknown effects on the 
CV system. For instance, given that SHBG production is inhibited by high insulin levels as 
described in the introduction (9), insulin could be a possible pathophysiological link between 
SHBG, dysglycemia and CVD. The results in Study III underline that SHBG should be 
considered when evaluating androgen status in men with dysglycemia and CVD.
In contrast to the lack of prognostic impact of total testosterone in men with established 
CAD or high CV risk in Studies I and III, both total and free testosterone predicted CV and 
all-cause mortality in controls in Study I. As described in the introduction, low testosterone 
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levels have been associated with increased CV events and all-cause mortality in some, but 
not all, population-based studies (56-58, 61, 62, 118-120). This suggests that testosterone 
might be a more important prognostic marker in healthy individuals compared to those 
already afflicted with disease where other, traditional risk factors are of greater importance. 
Testosterone may be a mediator in CVD and prognosis rather than a traditional risk factor. 
If testosterone have direct effects on the CV and metabolic systems or if it is a marker of 
underlying disease is not clear but the effects of testosterone on several CV risk factors, 
such as dysglycemia, dyslipidemia, inflammation and the metabolic syndrome as well as 
atherosclerosis have been suggested as part of a potential link between testosterone and 
CVD (Figure 4) (121). For instance, epidemiological studies have shown that men with 
low testosterone have an increased risk of developing diabetes (89, 122) and a randomized 
clinical trial showed improving fasting glycemic control and reduced homeostatic model of 
insulin resistance in men with diabetes prescribed testosterone therapy (27). Whether low 
testosterone causes T2DM or vice versa or if it is merely a marker of a hyperglycemic and 
insulin resistant condition is not known but there is likely a bidirectional relationship.
 
The present findings showed an association between testosterone and prognosis in men 
without CVD but do not support a relation between low testosterone and CVD in men with 
such conditions. There are, to the best of our knowledge, no available results from randomized 
controlled trials investigating the impact of testosterone therapy on CV events to date. 
Interestingly, despite the lack of a clear association between endogenous testosterone and CV 
prognosis, testosterone therapy in men with CAD have shown effects on exercise-induced 
ischemia, myocardial perfusion, peripheral vascular resistance, cardiac electrophysiology 
and cardiac output in mechanistic studies (123-125). Further studies, preferably randomized 
controlled clinical trials, are warranted to clarify this relationship. 
Testosterone and SHBG in women
As expected, testosterone levels were lower in females (Study IV) than in males (Study 
III) in the ORIGIN biomarker substudy. They were, however, higher (123 ng/dl) than 
anticipations based on previous studies (126). This may be related to the assay method as 
already discussed. Another potential reason is the high prevalence of dysglycemia in the 
present population. In women, diabetes is associated with high testosterone levels (89). In a 
study by Wehr et al, women were categorized according to quartiles of free testosterone. In 
the first/lowest quartile, 24% had diabetes and mean total testosterone was 40 ng/dl. In the 
fourth/highest quartile, 47% had diabetes and mean total testosterone was 121 ng/dl, similar 
to the mean level found in Study IV (123 ng/dl). 
In Study IV, neither total nor free testosterone were associated with any of the outcomes. 
The results are in line with some observational studies in which there was no association 
between testosterone and prognosis (127, 128). But, as described in the introduction, there are 
contradictory findings i.e. some investigations with an association between low testosterone 
and increased CV risk (91, 92) and others indicating that high testosterone is deleterious 
for CV health (126, 129). As for men, the discrepant results may relate to comorbidities 
but also the hormonal fractions studied and the assays used. Moreover, the possibility of 
a U or J-shaped relation needs to be considered, e.g. as shown in a population-based study 
comprising elderly women (mean age=75 years) where participants both in the lowest and 
highest quartiles had a higher prevalence of coronary heart disease than those in the second 
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quartile (130). It has been hypothesized that changes in estrogens and androgens during 
menopause may mediate the increased risk of CVD in post-menopausal women (131, 132).
However, this was not shown for testosterone in women with dysglycemia and high CV risk 
in Study III and estrogens were not studied.
In contrast to testosterone, low levels of SHBG were associated with decreased risk of all-
cause mortality in women (Study IV). This association is less well-studied in women than 
in men. While some studies suggest a U-shaped relationship similar to that for testosterone 
(92, 133) other investigations did not show any prognostic relationship at all (127, 128, 
134, 135). In a subgroup analysis of the Multi-Ethnic Study of Atherosclerosis (n=2 834 
postmenopausal women) comprising women not on hormonal therapy (n=1 934), high levels 
of SHBG and low levels of free testosterone and estradiol were related to an increased risk of 
coronary heart disease. As described above for men, the effects of SHBG in Study IV could 
be testosterone-related but the lack of predictive ability of testosterone indicates that other, 
testosterone independent pathways may be more important, possibly through insulin levels as 
described above for men. More studies on sex hormones and CVD are needed to clarify this 
relationship, and testosterone should not be investigated without considering SHBG levels.
CAG repeat length and testosterone
Study II hypothesized that CAG repeat length would be associated with testosterone levels, 
but it did not correlate with testosterone measured at the four time points up to a year 
following an AMI and was not correlated to CV risk factors either. 
As described in the introduction, CAG repeat length is thought to be inversely correlated with 
transcriptional activity of the androgen receptor, thus influencing androgen responsiveness 
and possibly explaining phenotype variability beyond what can be deduced from testosterone 
measurements (136). Shorter CAG repeat length has been associated with an increased risk 
of incident low testosterone in German men during follow-up for five years (137). On the 
other hand, there was no difference in testosterone levels in people with CAG ≤ or >21 in a 
nested case-control study comprising 172 Norwegian men which supports the results from 
Study II (138). The Norwegian study also demonstrated that men with more components 
of the metabolic syndrome had shorter CAG repeat length. This could explain the slightly 
lower median CAG (=20) in Study II given the high proportion of dysglycemia compared 
to the expected mean of a Caucasian population (=21-22) (1). Shorter CAG repeat length 
have previously been associated with both a protective CV risk profile such as low body fat 
mass and plasma insulin (139) as well as a worse risk profile with low HDL-levels, metabolic 
syndrome, higher fasting glucose, HbA1c and reduced endothelial response to ischemia as 
measured by vascular ultrasound (138, 140). This could not be verified in Study II, and 
furthermore there was no relation between CAG repeat length and cardiometabolic risk 
factors in the German study either (137). 
A study of 474 men with T2DM showed that high testosterone levels were associated with 
decreased mortality in those with longer CAG repeat length while an increased mortality was 
seen in those with shorter CAG repeat length. The authors suggested that CAG repeat length 
modulates the prognostic capacity of testosterone (141). Another hypothesis in Study II was 
thus that CAG repeat length would be associated with CV outcomes. Although more patients 
Anne Wang
46
with CAG repeat length above median died from all-cause mortality, it was nominally but not 
significantly associated with all-cause death in age-adjusted analyses and not associated with 
CV events at all. Due to limited number of events, subgroup analyses with low or normal 
testosterone levels were not performed. In line with these study results, CAG repeat length 
was not related to any increased risk of CVD or myocardial infarction in a case-control study 
in 544 men (142). While this corroborates the results of Study II, the lack of association 
could also be related to the limited sample size.
If low testosterone in those with short CAG repeat length is a consequence of a more sensitive 
androgen receptor and not in itself related to testosterone deficient symptoms, this could 
confound associations seen in observational studies and partly explain the diverging results. 
Methodological considerations
Strengths
This thesis is based on data from the prospective cohort study GAMI (Studies I and II) and 
the biochemical substudy from the clinical trial ORIGIN (Studies III and IV). The GAMI and 
ORIGIN study populations represent patients with different levels of dysglycemia including 
prediabetes (IGT/IFG) and diabetes as well as different stages of CVD. 
GAMI consists of a well-defined, consecutive cohort of patients with AMI and a well-matched 
control group. The follow-up period was very long (11 years) with few patients lost to follow-
up. Events were carefully collected, ascertained and adjudicated by the investigators using 
direct information from patients, hospital records and national registries. Testosterone was 
measured using LC/MS which is considered gold standard. 
ORIGIN was a large, multicenter, randomized controlled trial. Follow-up time was six 
years, outcome data was determined by an adjudication committee and the primary outcome 
was known in 99% (n=12 443) of all patients. The biomarker substudy was based on a 
standardized collection, processing and storage of the blood samples. Moreover, routine 
clinical and biochemical measurements were available in all consenting participants.
Limitations
The number of patients in Studies I and II was limited making subgroup analyses, e.g. as 
tertiles or quartiles, difficult due to lack of statistical power. Another limitation was that 
some patients did not have testosterone levels measured at each time point due to technical 
problems or their condition. Moreover although testosterone was measured at several time 
points, the prognostic analyses were based on a single measurement in patients and controls. 
In Studies III and IV, testosterone levels were only obtained at one occasion though 
guidelines recommend measurement at two different occasions due to day-to-day variations. 
However, a single sample may be sufficient for epidemiological analyses (143). Information 
on testosterone treatment was not gathered for Studies I-III. Testosterone was measured 
using multiplex analyses, a kind of immunoassay, which as mentioned previously have a 
higher variability and inaccuracy compared to LC-MS/MS. Since this is of particular 
importance at low hormone levels, it is an important aspect to consider in women. The mean 
testosterone was indeed higher in the cohort of Study IV compared to previous studies which 
could be attributed to the use of the immunoassay. However, immunoassay has been used to 
measure testosterone in many previous studies in females (91, 126, 144). Moreover, although 
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the prevalence of PCOS as well as treatment with testosterone was likely low, information on 
this was not gathered and could have contributed to the higher testosterone levels observed. 
Another limitation in all studies was that free testosterone was not measured but calculated 
by means of the Vermeulen algorithm. The estimate of free testosterone is important, 
especially in individuals with dysglycemia where SHBG levels may be altered, as is the case 
with the present study cohorts. Free testosterone can be measured using equilibrium dialysis 
which is considered the reference method, however the method is technically demanding 
and not widely available (16). Therefore, the Endocrine Society recommended in their 2010 
guidelines the use of calculated free testosterone which is considered to provide satisfactory 
estimates if adequate assay methods are not available (18). As described in the introduction, 
in addition to the frequently used formula by Vermeulen et al., Zakharov et al. recently 
suggested another formula based on a different theory of binding mechanisms between 
testosterone and SHBG (22, 23). This was mentioned in the 2018 guidelines by the Endocrine 
Society, recommending measurement of free testosterone by equilibrium dialysis first of 
all and if this is unavailable, calculation by means of the Vermeulen or Zakharov formulas 
underlining that the latter, allosteric model, is more accurate and provides estimates close to 
values measured using equilibrium dialysis (23). Unfortunately, the Zakharov formula was 
not available at the time when Study I was conducted. A benefit of using the Vermeulen 
formula is that the study results are easier to compare with previous studies since currently it 
is the most frequently used formula.
Moreover, testosterone was dichotomized in Studies I-III according to the Endocrine Society 
guidelines to reflect the thresholds used in clinical practice, where low testosterone levels 
are diagnosed based on specific cut-off levels. Dichotomization makes the results easier to 
transfer to clinical practice, but also presents a simplified view of the continuous variable 
of testosterone. As previously discussed, there could be a U-shaped relationship between 
testosterone and the studied outcomes which suggest that for study purposes, the use of 
quartiles or cubic splines might provide more accurate estimates. However, these data could 
be more difficult to translate into clinically useful conclusions.
Ethical considerations
Testosterone levels were investigated in populations that are usually not targeted for sampling 
of testosterone and the prevalence of low testosterone levels was quite high (13-30%). 
Therefore, an important question is whether screening for testosterone levels in the absence 
of symptoms should be offered in such patients in clinical practice. Such screening cannot 
be advocated until several ethical considerations have been discussed. The Wilson-Jungner 
screening criteria outline a number of conditions that should be fulfilled before general 
screening can be accepted (145, 146). First of all, low testosterone levels without symptoms 
can not be considered an important health problem given current data. Furthermore, the 
natural history of low testosterone, and the potential link to CVD is not fully understood. 
Although there are tests available to detect low testosterone levels, there are issues with assay 
methods, diverging thresholds for total testosterone and the lack of a harmonized reference 
range for free testosterone. Contemporary guidelines do in general not recommend treatment 
for men with low testosterone levels in the absence of symptoms related to testosterone 
deficiency. Thus, screening for low testosterone levels cannot be recommended in clinical 
practice from an ethical point of view.
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Future perspectives
Testosterone and the prognosis in individuals with dysglycemia and CVD were investigated 
in observational studies in which SHBG in particular but low free testosterone as well 
were potential prognostic markers and of importance to consider in a pathophysiological 
perspective when trying to understand the link between dysglycemia and CVD.
 
The increased CV risk in dysglycemic individuals has been studied previously and traditional 
risk factors cannot fully explain this relation. Interestingly, increase in the homeostasis 
model assessment - estimated insulin resistance (HOMA-IR) has been related to impaired 
CV survival in patients with T2DM (147). SHBG has been closely linked to T2DM in 
observational and Mendelian randomization analyses and its synthesis in the liver is inhibited 
by high insulin levels (16, 81, 148). Thus during the progress of dyglycemia, high insulin 
levels in the early phase could result in low SHBG levels and as insulin levels decrease over 
time SHBG levels might start to increase. One hypothesis is therefore that SHBG could be a 
marker for insulin status and through this possibly the progress of diabetes which could have 
prognostic implications. Future studies need to clarify the link between SHBG and insulin 
by investigating SHBG, HOMA-IR and insulin levels with CV events to assess if and why 
SHBG can identify dysglycemic individuals at high risk.
 
Observational data are somewhat inconsistent on the relationship beween endogenous 
testosterone and CVD. Furthermore, in retrospective and clinical studies, concerns have been 
raised about the safety of testosterone therapy (149-152). However, a recent meta-analysis 
comprising 39 RCTs and 10 observational studies found no association between testosterone 
therapy and CV events (153). To close the gaps in knowledge and increase the understanding 
about testosterone and its potential cardiac effects, it is essential to study this further in 
clinical trials. Several small randomized controlled trials in men with CAD have reported 
on potential beneficial cardiac effects of testosterone (15, 29, 125). For example, short-term 
testosterone therapy by one-time injection as well as transdermal administration up to 12 
weeks have shown improvements in exercise-induced myocardial ischemia (123, 154). 
Mechanistic studies have suggested effects on coronary blood flow and improved myocardial 
function as part of the explanation. Interestingly, in a randomized, controlled cross-over study 
comprising men with hypogonadism and CAD (n=22), oral testosterone substitution for eight 
weeks showed beneficial effects on myocardial perfusion in areas supplied by unobstructed 
coronary arteries but not in obstructed areas (124). Future studies should investigate longer-
term testosterone therapy in men with CVD, preferably administered by intramuscular 
injection because of better compliance and absorption to assure raising low testosterone 
levels above threshold. Moreover, the use of cardiac magnetic resonance imaging could be 
of benefit for a more detailed assessment of myocardial perfusion, vascular function and CV 
physiology. This would shed some light over the possible pathophysiological mechanisms 
between testosterone and CVD. Finally, a randomized controlled trial on testosterone therapy 
and CV events is essential to confirm whether it is safe to administer from a CV perspective 
and if there is an impact of testosterone substitution on prognosis.
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CONCLUSIONS
1) Testosterone levels decrease following an AMI, with the lowest levels in men with 
dysglycemia. They increase to levels similar to those in healthy controls when measured 
one-year post-infarction. The initial reduction may be a reaction to stress due to AMI. 
Testosterone samples taken in close proximity to an AMI should be interpreted with 
caution. 
2) CAG repeat length was not correlated to testosterone levels and did not predict future 
CV events in men with AMI.
3) Testosterone predicted CV and all-cause mortality in healthy controls but not in patients 
with AMI. On the other hand, free testosterone <7 ng/dl was associated with all-cause 
mortality in men with dysglycemia and high CV risk. This suggests that testosterone 
may be a mediator in CVD and prognosis rather than a traditional risk factor.
4) SHBG was an independent predictor of CV events and all-cause mortality in men and 
for all-cause mortality in women with dysglycemia and high CV risk. Further studies 
are warranted to explore whether this action is mediated through an impact on the 
distribution of testosterone or if SHBG is a direct prognostic marker.
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